SFM
CCXI

Signet Financial Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Signet Financial Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,186
Closed -$43K – 1451
2021
Q4 		$43K Buy
+1,186
New +$41.6K 0.01% 535

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Signet Financial Management's CCXI Position: Q1 2022 in Review

Signet Financial Management sold out of ChemoCentryx, Inc. (CCXI) in Q1 2022, closing a stake of 1,186 shares — an estimated $43K sold.

Signet Financial Management first reported a position in CCXI in Q4 2021 and held it in 1 quarter. The position peaked at $43K in Q4 2021. 176 funds tracked by Wall St. Rank hold CCXI as of Q1 2022.

  • Signet Financial Management reported no remaining ChemoCentryx, Inc. position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 1,186 ChemoCentryx, Inc. shares in Q1 2022, an estimated $43K.
  • Signet Financial Management first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's ChemoCentryx, Inc. position peaked at $43K in Q4 2021.
  • 176 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.